Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467

Study Overview

• Status: Completed
• Conditions: Hepatitis B, Chronic
• Intervention / Treatment: Drug: ARB-001467; Other: Placebo

Detailed Description

Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • Monash Health, Gastroenterology and Hepatology
    • Melbourne, Victoria, Australia, 3004
      • The Alfred, Gastroenterology and Hepatology
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • Linear Clinical Research Ltd
• New Zealand
  • Auckland, New Zealand, 1010
    • Auckland Clinical Studies Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Documented chronic HBV infection for ≥12 months prior to Screening Visit.
• Quantitative HBsAg ≥1000 IU/mL at the Screening Visit.
• Subjects currently receiving entecavir and/or tenofovir for ≥12 months and HBV DNA undetectable.

Key Exclusion Criteria:

• Known co-infection with HIV, hepatitis C virus, and hepatitis D virus.
• Receiving or planning to receive systemic immunosuppressive medications during the study or ≤2 months prior to the first dose of study treatment.
• Receiving or planning to receive interferon during the study or ≤12 months prior to the first dose of study treatment.
• Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.
• Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the Screening Visit.
• Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 0.2 mg/kg ARB-001467 or Placebo; HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months	Drug: ARB-001467; An IV infusion of ARB-001467; Other: Placebo; An IV infusion of placebo; Other Names: 0.9% sodium chloride
Experimental: 0.4 mg/kg ARB-001467 or Placebo; HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months	Drug: ARB-001467; An IV infusion of ARB-001467; Other: Placebo; An IV infusion of placebo; Other Names: 0.9% sodium chloride
Experimental: ARB-001467 or Placebo; HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months	Drug: ARB-001467; An IV infusion of ARB-001467; Other: Placebo; An IV infusion of placebo; Other Names: 0.9% sodium chloride
Experimental: 0.4 mg/kg ARB-001467; HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks	Drug: ARB-001467; An IV infusion of ARB-001467

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment.	To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy	28 days post last infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (cohort 1-3) and Week 36 (Cohort 4).	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf) partial, AUCs, T1/2, volume of distribution (VD) and clearance (CL) -baseline through Day 85 or Week 36.	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Evaluate antiviral activity of ARB 001467 for up to 72 weeks after the first dose of study treatment.	The proportion of subjects in each dose level cohort with ≥0.5 log10 HBsAg decrease from baseline at EOS, and for these subjects, the changes from baseline (expressed as percentage and log10 change) in the following virologic markers will be assessed throughout the study: Quantitative HBV surface antigen (HBsAg); Quantitative HBV surface antibody (HBsAb); Quantitative HBV DNA and HBV-RNA (viral load) For the HBeAg positive cohort only: - Quantitative HBV e antigen (HBeAg)	Up to 18 months

Collaborators and Investigators

• Sponsor: Arbutus Biopharma Corporation
• Investigators: Study Chair: Patricia Mendez, MD, PhD, Arbutus Biopharma Corporation

Study record dates

Study Major Dates

• Study Start: December 1, 2015
• Primary Completion (Actual): May 18, 2018
• Study Completion (Actual): May 18, 2018

Study Registration Dates

• First Submitted: December 7, 2015
• First Submitted That Met QC Criteria: December 14, 2015
• First Posted (Estimate): December 15, 2015

Study Record Updates

• Last Update Posted (Actual): June 29, 2018
• Last Update Submitted That Met QC Criteria: June 28, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Hepatitis, Chronic; Hepatitis; Hepatitis B; Hepatitis B, Chronic
• Other Study ID Numbers: ARB-001467-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided